Soter Bio

Soter Bio is a San Francisco-based biotechnology company focused on developing next-generation therapies for autoimmune and inflammatory diseases. The company leverages its expertise in protein engineering to create highly selective modulators of the immune system, with a primary focus on enhancing regulatory T cell (Treg) function. Its lead programs involve engineered Interleukin-2 (IL-2) variants designed to selectively activate Tregs while avoiding the stimulation of pro-inflammatory effector cells. By restoring immune balance, Soter Bio aims to provide transformative treatments for patients with chronic inflammatory conditions such as systemic lupus erythematosus and inflammatory bowel disease. The company is led by experienced industry veterans from Amgen and Genentech and is backed by prominent life science venture capital firms.